These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1304575)

  • 1. Weak magnetic fields in the treatment of Parkinson's disease with the "on-off" phenomenon.
    Sandyk R
    Int J Neurosci; 1992 Sep; 66(1-2):97-106. PubMed ID: 1304575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic fields in the treatment of Parkinson's disease.
    Sandyk R; Anninos PA; Tsagas N; Derpapas K
    Int J Neurosci; 1992 Mar; 63(1-2):141-50. PubMed ID: 1342026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weak magnetic fields antagonize the effects of melatonin on blood glucose levels in Parkinson's disease.
    Sandyk R
    Int J Neurosci; 1993 Jan; 68(1-2):85-91. PubMed ID: 8063518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Parkinson's disease with magnetic fields reduces the requirement for antiparkinsonian medications.
    Sandyk R
    Int J Neurosci; 1994; 74(1-4):191-201. PubMed ID: 7928105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further observations on the unique efficacy of picoTesla range magnetic fields in Parkinson's disease.
    Sandyk R; Derpapas K
    Int J Neurosci; 1993; 69(1-4):167-83. PubMed ID: 8083004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of micrographia in Parkinson's disease by application of picoTesla range magnetic fields.
    Sandyk R; Iacono RP
    Int J Neurosci; 1994 Jul; 77(1-2):77-84. PubMed ID: 7989163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone attenuates the antiparkinsonian effects of picoTesla range magnetic fields.
    Sandyk R; Iacono RP
    Int J Neurosci; 1994 Sep; 78(1-2):111-22. PubMed ID: 7829285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Freezing of gait in Parkinson's disease is improved by treatment with weak electromagnetic fields.
    Sandyk R
    Int J Neurosci; 1996 Mar; 85(1-2):111-24. PubMed ID: 8727687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinsonian micrographia reversed by treatment with weak electromagnetic fields.
    Sandyk R
    Int J Neurosci; 1995 Mar; 81(1-2):83-93. PubMed ID: 7775074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic fields in the therapy of parkinsonism.
    Sandyk R
    Int J Neurosci; 1992 Oct; 66(3-4):209-35. PubMed ID: 1305620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.
    Mouradian MM; Juncos JL; Fabbrini G; Chase TN
    Ann Neurol; 1987 Oct; 22(4):475-9. PubMed ID: 3435068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
    Mouradian MM; Juncos JL; Fabbrini G; Schlegel J; Bartko JJ; Chase TN
    Ann Neurol; 1988 Sep; 24(3):372-8. PubMed ID: 3228271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locus coeruleus-pineal melatonin interactions and the pathogenesis of the "on-off" phenomenon associated with mood changes and sensory symptoms in Parkinson's disease.
    Sandyk R
    Int J Neurosci; 1989 Nov; 49(1-2):95-101. PubMed ID: 2691423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wearing off: A complex phenomenon often poorly recognized in Parkinson's disease. A study with the WOQ-19 questionnaire.
    Pistacchi M; Gioulis M; Sanson F; Marsala SZ
    Neurol India; 2017; 65(6):1271-1279. PubMed ID: 29133700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with weak electromagnetic fields restores dream recall in a parkinsonian patient.
    Sandyk R
    Int J Neurosci; 1997 Jun; 90(1-2):75-86. PubMed ID: 9285289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Jaw movement dysfunction related to Parkinson's disease and partially modified by levodopa.
    Robertson LT; Hammerstad JP
    J Neurol Neurosurg Psychiatry; 1996 Jan; 60(1):41-50. PubMed ID: 8558149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.
    Fénelon G; Giménez-Roldán S; Montastruc JL; Bermejo F; Durif F; Bourdeix I; Péré JJ; Galiano L; Schadrack J
    J Neural Transm (Vienna); 2003 Mar; 110(3):239-51. PubMed ID: 12658373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Various aspects of motor fluctuations and their management in Parkinson's disease.
    Mizuno Y; Kondo T; Mori H
    Neurology; 1994 Jul; 44(7 Suppl 6):S29-34. PubMed ID: 8047258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
    Bravi D; Mouradian MM; Roberts JW; Davis TL; Sohn YH; Chase TN
    Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease.
    Martinu K; Degroot C; Madjar C; Strafella AP; Monchi O
    Eur J Neurosci; 2012 Feb; 35(4):572-83. PubMed ID: 22304628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.